Abstract A055: Addressing disparate outcomes in triple negative breast cancer: Targeting metabolic and cell-cycle vulnerabilities with novel biguanide-mediated combination therapy
Triple-negative breast cancer (TNBC) is an aggressive subtype defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Despite constituting 12.7% of breast cancer (BC) cases, TNBC comprises 40% of BC mortalities with a three-fold increase in ea...